Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Veitz, M.
Periocular steroids in non-infectious uveitis: 6 month outcomes
Humanmedizin; [ Diplomarbeit ] Graz Medical University; 2018. pp. 50
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Seidel Gerald
- Altmetrics:
- Abstract:
- Introduction: Steroids are the mainstay short term treatment for non-infectious uveitis. The exposure of the globe makes the eye especially suited for local application of these drugs, thus avoiding or diminishing many of the systemic complications of steroids. For this purpose, steroids are used in the form of drops and intraocular or periocular injections. The latter offer high intraocular drug concentrations by a well-tolerated in office procedure leaving the globe intact, which virtually eliminates the intraocular injection’s risk of severe complications such as endophthalmitis. Periocular steroids have been shown to be efficacious, but their risk benefit profile has been insufficiently characterized. Methods: In this retrospective analysis, we reviewed the charts of 100 eyes of 86 patients with the diagnosis of uveitis who had received a periocular corticosteroid injection at any time between 2006 and 2016 at the department of Ophthalmology at the Medical University of Graz. Basic demographic information as well as intraocular pressure and best visual acuity were collected and statistically analysed. Results: The results show that eyes treated with periocular steroids show a significant improvement in visual acuity one month (p<0.001) as well as the six months after treatment (p<0.001). Patients also showed a statistically significant rise in intraocular pressure from baseline at the one month (p<0.001) as well as at six months (p<0.001). However, only 11.11% showed an intraocular pressure increase of more than 10 mmHg. Conclusion: The treatment of uveitis patients with a periocular steroid injection shows an improvement of visual acuity within the first month after the injection, but also a significant rise of intraocular pressure.